“Maintenance of Response With Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s23. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/125.